Comparison of Progression of Coronary Calcium in Postmenopausal Women on Versus Not on Estrogen/Progestin Therapy - 15/08/11
, Alexander Leber, MD a, Franz von Ziegler, MD a, Christoph Becker, MD b, Andreas Knez, MD a
Corresponding author: Tel: 49-89-7095-2229; fax: 49-89-7095-2224.Résumé |
The prophylactic effect of postmenopausal hormone replacement therapy on coronary atherosclerosis remains controversial. We, therefore, examined the influence of combined estrogen/progestin therapy on the progression of coronary calcium as a marker of coronary atherosclerosis. We determined the extent of coronary calcium in 277 women (age 57 ± 6 years, time after menopause 3.9 ± 2.4 years, group I) at the beginning of hormone replacement therapy using multislice computed tomography. For quantification, we calculated the volume score. After an observation period of 3 years, we determined the progression of coronary calcium in a second scan. The results were compared with those from an age- and risk factor-adjusted group of postmenopausal women without hormone substitution (group II). No significant difference was found in the volume score (59 ± 95 vs 58 ± 88) or risk factor distribution between the 2 groups on study entry. In 56 women of group I and 52 women of group II, coronary calcium could be excluded on the initial scan (p = NS). After a mean observation time of 38.5 ± 4.9 months, we observed no significant difference between the 2 groups regarding an increase in volume score (17 ± 24 vs 19 ± 27, p = NS) or the fraction of women with an increase in volume score (82.2% vs 84.2%). In conclusion, a reduced progression of coronary calcium in postmenopausal women on combined estrogen/progestin therapy could not be observed compared with a matched group of women without hormone substitution.
Le texte complet de cet article est disponible en PDF.Plan
Vol 99 - N° 3
P. 374-378 - février 2007 Retour au numéro
Article précédent
- Relation of the “Hypertriglyceridemic Waist” Phenotype to Earlier Manifestations of Coronary Artery Disease in Patients With Glucose Intolerance and Type 2 Diabetes Mellitus
- Julie St-Pierre, Isabelle Lemieux, Patrice Perron, Diane Brisson, Marta Santuré, Marie-Claude Vohl, Jean-Pierre Després, Daniel Gaudet
- Safety of Lovastatin/Extended Release Niacin Compared With Lovastatin Alone, Atorvastatin Alone, Pravastatin Alone, and Simvastatin Alone (from the United States Food and Drug Administration Adverse Event Reporting System)
- Alawi A. Alsheikh-Ali, Richard H. Karas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?